Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CDK5RAP3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CDK5RAP3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CDK5RAP3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CDK5RAP3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CDK5RAP3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CDK5RAP3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CDK5RAP3_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CDK5RAP3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0071900 | Colorectum | AD | regulation of protein serine/threonine kinase activity | 98/3918 | 359/18723 | 2.18e-03 | 1.73e-02 | 98 |
GO:0007346 | Colorectum | AD | regulation of mitotic cell cycle | 119/3918 | 457/18723 | 4.60e-03 | 3.14e-02 | 119 |
GO:00421761 | Colorectum | SER | regulation of protein catabolic process | 126/2897 | 391/18723 | 5.33e-17 | 2.52e-14 | 126 |
GO:19033621 | Colorectum | SER | regulation of cellular protein catabolic process | 91/2897 | 255/18723 | 1.22e-15 | 5.36e-13 | 91 |
GO:19038291 | Colorectum | SER | positive regulation of cellular protein localization | 86/2897 | 276/18723 | 3.61e-11 | 6.11e-09 | 86 |
GO:00224111 | Colorectum | SER | cellular component disassembly | 114/2897 | 443/18723 | 1.17e-08 | 9.59e-07 | 114 |
GO:00487321 | Colorectum | SER | gland development | 112/2897 | 436/18723 | 1.75e-08 | 1.28e-06 | 112 |
GO:00349761 | Colorectum | SER | response to endoplasmic reticulum stress | 74/2897 | 256/18723 | 3.01e-08 | 2.05e-06 | 74 |
GO:19033201 | Colorectum | SER | regulation of protein modification by small protein conjugation or removal | 70/2897 | 242/18723 | 6.84e-08 | 4.42e-06 | 70 |
GO:19001801 | Colorectum | SER | regulation of protein localization to nucleus | 46/2897 | 136/18723 | 8.50e-08 | 5.27e-06 | 46 |
GO:00313961 | Colorectum | SER | regulation of protein ubiquitination | 62/2897 | 210/18723 | 1.69e-07 | 9.71e-06 | 62 |
GO:19001821 | Colorectum | SER | positive regulation of protein localization to nucleus | 33/2897 | 87/18723 | 2.81e-07 | 1.52e-05 | 33 |
GO:00098951 | Colorectum | SER | negative regulation of catabolic process | 84/2897 | 320/18723 | 3.93e-07 | 2.06e-05 | 84 |
GO:00313301 | Colorectum | SER | negative regulation of cellular catabolic process | 70/2897 | 262/18723 | 1.79e-06 | 7.70e-05 | 70 |
GO:19033631 | Colorectum | SER | negative regulation of cellular protein catabolic process | 28/2897 | 75/18723 | 3.17e-06 | 1.25e-04 | 28 |
GO:00513481 | Colorectum | SER | negative regulation of transferase activity | 70/2897 | 268/18723 | 4.27e-06 | 1.62e-04 | 70 |
GO:00610081 | Colorectum | SER | hepaticobiliary system development | 45/2897 | 150/18723 | 4.98e-06 | 1.85e-04 | 45 |
GO:00345041 | Colorectum | SER | protein localization to nucleus | 74/2897 | 290/18723 | 5.74e-06 | 2.05e-04 | 74 |
GO:00018891 | Colorectum | SER | liver development | 44/2897 | 147/18723 | 6.73e-06 | 2.35e-04 | 44 |
GO:00421771 | Colorectum | SER | negative regulation of protein catabolic process | 38/2897 | 121/18723 | 8.20e-06 | 2.76e-04 | 38 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDK5RAP3 | SNV | Missense_Mutation | novel | c.814N>T | p.Pro272Ser | p.P272S | Q96JB5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
CDK5RAP3 | SNV | Missense_Mutation | novel | c.1164C>A | p.Phe388Leu | p.F388L | Q96JB5 | protein_coding | deleterious(0.03) | probably_damaging(0.997) | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR |
CDK5RAP3 | SNV | Missense_Mutation | novel | c.371N>G | p.Glu124Gly | p.E124G | Q96JB5 | protein_coding | deleterious(0) | possibly_damaging(0.894) | TCGA-C8-A273-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CDK5RAP3 | SNV | Missense_Mutation | novel | c.371N>G | p.Glu124Gly | p.E124G | Q96JB5 | protein_coding | deleterious(0) | possibly_damaging(0.894) | TCGA-E9-A1NF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
CDK5RAP3 | insertion | Frame_Shift_Ins | novel | c.354_355insGGCCC | p.Met119GlyfsTer3 | p.M119Gfs*3 | Q96JB5 | protein_coding | | | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD |
CDK5RAP3 | insertion | Nonsense_Mutation | novel | c.355_356insGACTTTGAGAGGTCAGTCCCAT | p.Met119ArgfsTer3 | p.M119Rfs*3 | Q96JB5 | protein_coding | | | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD |
CDK5RAP3 | deletion | Frame_Shift_Del | novel | c.528delN | p.Ala177GlnfsTer32 | p.A177Qfs*32 | Q96JB5 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CDK5RAP3 | SNV | Missense_Mutation | | c.832C>T | p.Pro278Ser | p.P278S | Q96JB5 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-C5-A7CO-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
CDK5RAP3 | SNV | Missense_Mutation | | c.530N>A | p.Ala177Glu | p.A177E | Q96JB5 | protein_coding | tolerated(0.94) | benign(0.148) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
CDK5RAP3 | SNV | Missense_Mutation | | c.450G>T | p.Glu150Asp | p.E150D | Q96JB5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |